Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive earlystage and metastatic breast cancer. Diarrhe......
In this review, we evaluate the potential and recent advancements in using artificial intelligence techniques to de-escalate loco-regional breast canc......
Purpose: Weight gain after breast cancer is common. The aim of this study was to determine factors associated with weight gain after breast cancer in ......
Background: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestr......
